Abstract | BACKGROUND: METHODS: Target genes of atorvastatin were collected by the DrugBank database. Prediction of interaction between primary targets and secondary targets was performed, and protein-protein interaction network was constructed though the STRING. Then, KEGG pathway enrichment analysis was performed with WebGestalt and ClueGO, including the pathways in non-small cell lung cancer. Furthermore, a genomic alteration analysis of the selected seed genes of atorvastatin benefit and non-small cell lung cancer pathway was conducted by cBioPortal. Finally, a survival analysis with the selected seed genes in lung cancer ( lung adenocarcinoma, lung squamous cell carcinoma) was conducted using Kaplan-Meier (KM) plotter. RESULTS: CONCLUSION:
|
Authors | Lei Zhang, Yifang Huang, Xuedong Gan, Siying He, Xiaohuan Cheng, Na Yang, Siwei Li, Zuhua Li, Fang Zheng |
Journal | Anti-cancer agents in medicinal chemistry
(Anticancer Agents Med Chem)
Vol. 19
Issue 17
Pg. 2060-2071
( 2019)
ISSN: 1875-5992 [Electronic] Netherlands |
PMID | 31544704
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Antineoplastic Agents
- TP53 protein, human
- Tumor Suppressor Protein p53
- Atorvastatin
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Antineoplastic Agents
(adverse effects, chemistry, pharmacology)
- Atorvastatin
(adverse effects, chemistry, pharmacology)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, metabolism)
- Databases, Chemical
- Databases, Genetic
- ErbB Receptors
(antagonists & inhibitors, genetics, metabolism)
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, metabolism)
- Protein Interaction Maps
- Tumor Cells, Cultured
- Tumor Suppressor Protein p53
(antagonists & inhibitors, genetics, metabolism)
|